Highlights / Key Themes
- NEW!! EVENTSCOPE' ONLINE DELEGATE NETWORKING TOOL
- ANALYTICAL THINK TANK
- CEO PANEL: Achieving Growth in a Volatile Climate
- INTERACTIVE PANEL DISCUSSION ON KEY LEGAL ISSUES IN THE RUSSIAN PHARMACEUTICAL SECTOR
Each year you inform us that the networking opportunities are one of the real highlights of the Forum. Therefore to enhance this experience, we are introducing yet another networking platform for you. A few days before the Forum starts you will be sent unique log-in and password information to access a secure online networking system for this event which enables you to browse, search and contact other registered event attendees before, during and post event. View the list of participants and arrange meetings to take place during the event! Don't miss out - use this additional networking tool and you can be sure you will meet all the people you want to at the 2010 Forum!
This think tank will feature trusted experts in the sector, representing the leading market research companies. The panel will analyse the current reform process and its effects on various segments of the industry, and will present a detailed statistical review of the key market segments, therapy areas, products and companies, as well as evaluating key drivers and impediments to future market development.
This panel featuring CEO's of the leading pharmaceutical companies working in Russia, will share their thoughts on the future of market development, the needs of the business for the next decade, as well as analysing the most critical elements to any growth strategy.
This session will gather together experts from the leading legal companies specialising in pharmaceutical market to debate the practical problems that companies and legal counsels face in their day-to-day business and examine a variety of issues in commercial and contract law that affect company operations and profitability. Topics for discussion include: unfair competition, data protection and data exclusivity, advertising and promotion, pricing and subsidies, and many others



